Metabolic Adverse Events in Patients With Mental Illness Treated With Antipsychotics

Balf, Gabriela; Stewart, T. D.; Whitehead, Richard; Baker, Ross A.

doi:10.4088/pcc.v10n0104

Cited by 33 publications

(34 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Second-generation antipsychotics (SGAs) are generally preferred over typical antipsychotics for schizophrenia treatment as they are associated with fewer extrapyramidal symptoms (EPSs), lower risk of tardive dyskinesia, and possibly greater improvement in negative symptoms. 4 However, several SGAs are known to be associated with a high risk of metabolic adverse effects such as weight gain, hyperlipidemia, and hyperglycemia. 4,5 Glucose dysregulation, 6 glucose intolerance, 7 and increased cholesterol levels 8 can frequently occur in patients taking SGAs.…”

mentioning

confidence: 99%

Paliperidone Palmitate and Metabolic Syndrome in Patients With Schizophrenia

Rosso

Pessina

Martini

et al. 2016

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

Oral and long-acting injectable second-generation antipsychotics are known to be associated with a high risk of metabolic adverse effects. Together with other drug treatments, poor lifestyle choices, and genetic liability, they contribute to development of metabolic syndrome (MetS), which occurs in nearly one third of patients with schizophrenia.The primary objective of this multicenter prospective observational study was to explore the prevalence of MetS in a sample of 60 real-world patients treated with paliperidone palmitate (PP) over a period of 12 months. The secondary objectives were to assess other tolerability aspects and the efficacy of PP on schizophrenic symptoms.The proportion of patients with MetS at baseline (33%) did not significantly change neither at 6 (39.0%) nor at 12 months (29.5%) of PP treatment. The same applies to each individual component of MetS. We found a slight but statistically significant increase in body mass index (26.3 ± 6.0 vs 27.1 ± 4.6, P = 0.031) and of waist circumference (98.2 ± 17.9 vs 100.3 ± 15.9, P = 0.021) from baseline to end point. Weight gain was detected in approximately 15% of patients.At least 1 mild or moderate adverse event was found in 71.3%, 88.0%, and 52.1% of patients, respectively, at baseline, 6 months, and 12 months. A significant improvement in schizophrenic symptoms emerged by means of Positive and Negative Syndrome Scale total and subscale scores.Together with previous literature findings, our results seem to indicate that PP could be a valid therapeutic option for patients with a severe disorder and with a high metabolic risk profile.

show abstract

mentioning

confidence: 99%

Paliperidone Palmitate and Metabolic Syndrome in Patients With Schizophrenia

Rosso

Pessina

Martini

et al. 2016

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…While the mechanisms for weight gain are still unclear and direct, weight-independent mechanisms for at least some SGAs regarding glucose and lipid abnormalities have been discussed, it is clear that antipsychotics differ in their risk for adverse changes in body weight and metabolic dysregulation (Correll, 2007). As individuals with mental illness are more likely to be overweight or obese than the general population, weight should be routinely monitored in all patients, especially in those receiving treatment with atypical antipsychotic medications associated with weight gain (Balf et al, 2008).…”

Section: Resultsmentioning

confidence: 99%

“…In the past decades physical health monitoring of patients with severe mental disorder looked for the extrapyramidal symptoms and tardive dyskinesia often associated with conventional antipsychotics. Atypical antipsychotics were developed to overcome extrapyramidal side effects associated with the use of typical antipsychotics at clinically effective doses, and this has led to widespread use since their introduction over a decade ago (Balf et al, 2008). Despite these benefits, the use of second generation antipsychotics has also been associated with reports of dramatic weight gain, diabetes and atherogenic lipid profiles (Newcomer et al, 2002).…”

Section: The Time Of Monitoringmentioning

confidence: 99%

The Impact of Cardiometabolic Risk in Patients with Severe Mental Illness: From Evidence to Clinical Management

Sciascio¹,

Calò²

2011

Psychiatric Disorders - Worldwide Advances

View full text Add to dashboard Cite

“…Spoljašnji uzroci uključuju nezdrav stil života, pušenje, konzumiranje brze hrane, nedostatak fizičke aktivnosti i nuspojave farmakoterapije [4,5]. Antipsihotici takođe povećavaju rizik za razvoj metaboličkog sindroma i dijabetes melitusa [6].…”

Section: Uvodunclassified

Uloga porodice u liječenju bolesnika sa shizofrenijom

Stojcic¹

2016

Biomedicinska istraž.

View full text Add to dashboard Cite

Kratak sadržajUvod. Uključenost porodice u liječenje bolesnika je značajno, jer utiče na troškove i ishod oboljenja. Cilj rada je ispitati kolika je uključenost i podrška porodice u liječenju pacijenata oboljelih od shizofrenije. Metode.Uzorak je činilo 100 bolesnika sa dijagnozom shizofrenije koji su liječeni u JZU "Sveti apostol Luka" u Doboju. Uključeni su pacijenti oba pola stariji od 18 godina, od kojih 39 žena. Pacijenti su izabrani metodom slučajnog izbora. Kriterijum za uključivanje je bila dijagnoza shizofrenije postavljena od strane psihijatra. Za studiju je dizajniran upitnik koji omogućava uvid u sociodemografske podatke, dužinu, način liječenja, uključenost i podršku članova porodice tokom liječenja.Rezultati. Među ispitanim bolesnicima 42% se nikada nije ženilo, 21% je bilo razvedenih, a 31% u braku. Iz grupe razvedenih, 7/21 bolesnika je imalo preko tri komorbiditeta, dok je kod onih u braku komorbiditet imalo 3/31 bolesnika. Najčešći komorbiditet je bila hipertenzija (25 bolesnika) i hiperlipidemija (16 bolesnika). Proporcionalno veći broj razvednih bolesnika je hospitalizovan dva ili tri puta (7/22) u odnosu na one u braku (4/37). Stalna saradnja porodice i bolesnika postojala je kod 28%, povremena kod 32%, slaba kod 28%, a nikakva kod 14% bolesnika. Bolesnici kod kojih je saradnja sa porodicom slaba ili nije postojala imali su veći broj hospitalizacija (15/42 preko tri hospitalizacije) od onih čije su porodice sarađivale u liječenju (7/58 preko tri hospitalizacije).Zaključak. Kod manje od jedne trećine ispitanih bolesnika sa shizofrenijom postojala je stalna saradnja porodice u liječenju. Liječenje bolesnika bez podrške, saradnje i uključenosti članova porodice je povezano sa češćim pogoršanjima i hospitalizacijama.

show abstract

Metabolic Adverse Events in Patients With Mental Illness Treated With Antipsychotics

Abstract: There is a clear need for awareness among primary care physicians, particularly as metabolic effects of atypical antipsychotics such as blood pressure and glucose and lipid levels are possibly best monitored in a primary care setting.

Cited by 33 publications

References 48 publications

Paliperidone Palmitate and Metabolic Syndrome in Patients With Schizophrenia

Paliperidone Palmitate and Metabolic Syndrome in Patients With Schizophrenia

The Impact of Cardiometabolic Risk in Patients with Severe Mental Illness: From Evidence to Clinical Management

Uloga porodice u liječenju bolesnika sa shizofrenijom

Contact Info

Product

Resources

About